Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | UBE2N | P61088 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.45 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13237022 | 0.86 | FLT3 (0.53) | FLT3HDAC6MAPTPKN1PKN2 | |
| SCHEMBL13237025 | 0.82 | NAMPT (0.55) | RAD52FLT3GAAKDM4EMEN1 | |
| SCHEMBL13237021 | 0.82 | GSK3B (0.53) | RAD52FLT3HDAC6METHDAC3 | |
| SCHEMBL5255365 | 0.81 | GSK3B (0.38) | RAD52UBE2NHDAC6PKN1PKN2 | |
| SCHEMBL13237020 | 0.81 | FLT3 (0.45) | FLT3PKN1PKN2GSK3B | |
| SCHEMBL21017950 | 0.81 | HDAC6 (0.67) | HDAC6HDAC3HDAC1HDAC8 | |
| SCHEMBL13237016 | 0.80 | ATM (0.56) | HDAC6MAPTPKN1PKN2GAA | |
| SCHEMBL13237024 | 0.80 | FLT3 (0.48) | FLT3PKN1PKN2KDM4E | |
| SCHEMBL18164011 | 0.80 | RAD52 (0.44) | RAD52UBE2NFLT3HDAC6IKBKB | |
| SCHEMBL2941275 | 0.80 | PKN1 (0.54) | MAPTPKN1PKN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | disclosed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7470689-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2008-12-30 | — | — | US | disclosed |
| US-7470689-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2008-12-30 | — | — | US | disclosed |
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | CDK2, CDK1, CDK4 | RAD52 1711/4885UBE2N 866/4885FLT3 427/4885 |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | RAD52 4625/4885UBE2N 3800/4885FLT3 2422/4885 |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | CDK2, CDK1, CDK4 | RAD52 1795/4885UBE2N 877/4885FLT3 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.